公开(公告)号：KR1020000041160A

公开(公告)日：2000-07-15

申请号：KR1019980056952

申请日：1998-12-21

Applicant: 주식회사대성미생물연구소 ,  한국과학기술연구원

Inventor： 오태광 ,  김영옥 ,  이정기 ,  오병철 ,  김동현 ,  정준기 ,  박승춘 ,  김판경 ,  최양웅 ,  이동규

IPC: C12N15/63

CPC classification number: C12N15/63 ,  A23K10/16 ,  C12N9/14 ,  C12R1/125

Abstract: PURPOSE: Phytase expression vector, pJPK has strong BJ27 promoter. Bacillus subtilis pJPK (KCTC 0526BP) transformed with pJPK expresses phytase highly, secrets expressed protein and is nontoxic to animal because of lacking endotoxin such as lipopolysaccharides. CONSTITUTION: Bacillus expression vector pJH27, having strong promoter BJ27, is ligated with 2.2 kb phytase gene originated from Bacillus amyloliquefaciens DS-11. The 2.2kb DNA includes SD sequence of phytase gene complementary to Bacillus subtilis 16S rRNA sequence (UCCUCC) for the overexpression of phytase. Resulting recombinant plasmid, pJPK, is introduced into E. coli JM83. Purified pJPK is transformed into Bacillus subtilis DB104 by protoplast transformation. Modified LB medium is consisted of 1% of potassium phosphate, 0.045% of magnesium sulfate, 4% of glucose, 1% of tryptone, 0.5% of yeast extract, 0.5% of NaCl and trace elements. 500-1000 unit of phytase is added to 1kg of animal feed. Animal experiment with porcine reveals that phytase produced from bacillus effectively degrades phytic acid in the animal feed.

Abstract translation: 目的：植酸酶表达载体pJPK具有较强的BJ27启动子。 用pJPK转化的枯草芽孢杆菌pJPK（KCTC 0526BP）高度表达植酸酶，秘密表达蛋白质，由于缺乏内毒素，如脂多糖，对动物无毒。 构成：具有强启动子BJ27的芽孢杆菌表达载体pJH27与源自解淀粉芽孢杆菌DS-11的2.2kb植酸酶基因连接。 2.2kb DNA包括与枯草芽孢杆菌16S rRNA序列（UCCUCC）互补的植酸酶基因的SD序列，用于过表达植酸酶。 将得到的重组质粒pJPK导入大肠杆菌JM83中。 纯化的pJPK通过原生质体转化转化到枯草芽孢杆菌DB104中。 改性LB培养基由1％磷酸钾，0.045％硫酸镁，4％葡萄糖，1％胰蛋白胨，0.5％酵母提取物，0.5％NaCl和微量元素组成。 将500-1000单位的植酸酶加入1kg动物饲料中。 猪的动物实验显示，由芽孢杆菌产生的植酸酶有效降解动物饲料中的植酸。

公开(公告)号：KR100475647B1

公开(公告)日：2005-03-10

申请号：KR1020020026650

申请日：2002-05-15

Applicant: 한국과학기술연구원

Inventor： 이용섭 ,  김동현 ,  김형자 ,  박호군

IPC: A61K31/353

Abstract: 본 발명은 화학식 1 및 화학식 2로 표시되는 플라보노이드 화합물 또는 이를 포함하는 고삼 추출물을 유효성분으로 함유하는 성기능 장애 개선용 조성물에 관한 것으로, 상기 조성물은 cGMP 포스포디에스테라제 저해활성을 가짐으로써 발기부전 또는 발기 기능 장애와 같은 성기능 장애를 개선하는데 사용할 수 있다.
화학식 1

(상기식에서, R
1 , R
2 , R
3 , R
4 및 점선은 하기 명세서에 나타낸 바와 같다.)
화학식 2

公开(公告)号：KR101971158B1

公开(公告)日：2019-08-27

申请号：KR1020170114482

申请日：2017-09-07

Applicant: 한국과학기술연구원

Inventor： 정경윤 ,  김동현 ,  디키수산토 ,  박재호 ,  정지원 ,  정훈기 ,  장원영 ,  최원창 ,  조병원

IPC: G01N23/20 ,  H01M2/10

公开(公告)号：KR1020170114558A

公开(公告)日：2017-10-16

申请号：KR1020160041693

申请日：2016-04-05

Applicant: 한국과학기술연구원

Inventor： 정경윤 ,  김동현 ,  디키수산토 ,  노재교 ,  김수진 ,  박재호 ,  정훈기 ,  장원영 ,  조병원

IPC: G01N23/20 ,  G01N25/28 ,  G01N21/3504

CPC classification number: G01N23/20008 ,  G01N21/3504 ,  G01N25/28

Abstract: 투과형엑스선회절분석시스템용시료지지장치및 이를이용한투과형엑스선회절분석시스템이개시된다. 본발명의일 실시예에따른투과형엑스선회절분석시스템용시료지지장치는수평방향으로배치되는제1 지지프레임; 제1 지지프레임의상부에배치되어제1 지지프레임에의해지지되되, 단열기능을가지는본체부와본체부를관통하되시료가수용된쿼츠캐필러리(quartz capillary)가삽입되는쿼츠튜브(quartz tube)와쿼츠튜브와쿼츠캐필러리사이에배치되는히팅코일을구비하여시료를가열하고시료의열적평형상태를유지하게하는퍼니스; 및제1 지지프레임의양단부에각각착탈가능하게결합되되, 캐리어가스를공급하는가스공급관과쿼츠튜브의일단부를상호연통되게연결하고캐리어가스를배출하는가스배출관과쿼츠튜브의타단부를상호연통되게연결하는가스관연결부를포함한다.

公开(公告)号：KR100408928B1

公开(公告)日：2003-12-11

申请号：KR1020010018228

申请日：2001-04-06

Applicant: 한국과학기술연구원

Inventor： 진창배 ,  김동현 ,  이용섭 ,  정경자 ,  김형자

IPC: A61K31/70

Abstract: PURPOSE: A composition for the prevention and treatment of ischemic disease containing aloesin as an effective ingredient and a preparation containing the same is provided. Because aloesin as an aloe component has an excellent neuroprotective effect and nerve-ethological recovering effect, the composition containing the same can be effectively used in treatment of nerve cell and tissue damage caused by cerebral ischemia. CONSTITUTION: The composition for prevention and treatment of ischemia disease contains aloesin of the formula 1 £8-C-β -D-glucopyranosyl-7-hydroxy-5-methyl-2-(2-oxopropyl)-4H-1-benzopyran-4-one|, a pharmaceutically acceptable salt, hydrate or solvate or isomer and a pharmaceutically acceptable carrier thereof. The composition is formulated into a tablet, hard and soft gelatin capsule, liquid, suspension, injection, ointment, cream, gel or lotion. The composition is a neuroprotective composition for the prevention and treatment of ischemic apoplexy or concussion and a heart protecting composition for the prevention and treatment of ischemic myocardial infarction.

Abstract translation: 目的：提供一种含有芦荟苷作为有效成分的缺血性疾病的预防和治疗用组合物及含有该组合物的制剂。 由于芦荟芦荟成分具有优良的神经保护作用和神经行为恢复作用，因此含有该成分的组合物可以有效地用于治疗由脑缺血引起的神经细胞和组织损伤。 构成：用于预防和治疗局部缺血疾病的组合物含有式1＆8; 8-C＆amp;β的芦荟黄素; D-吡喃葡萄糖基-7-羟基-5-甲基-2-（2-氧代丙基）-4H-1-苯并吡喃-4-酮，其药学上可接受的盐，水合物或溶剂合物或异构体及其药学上可接受的载体。 该组合物被配制成片剂，硬和软明胶胶囊，液体，悬浮液，注射剂，软膏，乳膏，凝胶或洗剂。 该组合物是用于预防和治疗缺血性中风或脑震荡的神经保护组合物，以及用于预防和治疗缺血性心肌梗塞的心脏保护组合物。

公开(公告)号：KR1020020095286A

公开(公告)日：2002-12-26

申请号：KR1020010033382

申请日：2001-06-14

Applicant: 한국과학기술연구원

Inventor： 김중협 ,  김유승 ,  최경일 ,  김동현 ,  남길수 ,  서재홍

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: PURPOSE: Provided is a method for preparing novel pyrazolpyrimidine derivative represented by the formula(1) and its pharmaceutically acceptable salts or hydrates. A pharmaceutical composition containing it is used as a therapeutic agent for impotency by inhibition of phosphodiesterase V. CONSTITUTION: The novel pyrazolpyrimidine derivative represented by the formula(1), wherein R1 and R2 are independently C1-C6 alkyl or C3-C6 cycloalkyl; R3 is substituted or unsubstituted C1-C6 alkyl, C3-C6 cycloalkyl or C3-C6 alkenyl; and X is O or NR4 wherein R4 is hydrogen, OH or C1-C6 alkyl, C3-C6 cycloalkyl or C3-C6 alkenyl substituted or unsubstituted by alkoxy group. It is manufactured by the steps of: converting pyrazolopyrimidinone of the formula(2) into pyrazolopyrimidinethione of the formula(3) by thione reaction; chlorosulfonating the compound of the formula(3) into chlorosulfone compound of the formula(4) and letting the compound of formula(4) react with secondary amine to make the final compound of the formula(1).

Abstract translation: 目的：提供由式（1）表示的新型吡唑嘧啶衍生物及其药学上可接受的盐或水合物的制备方法。 通过抑制磷酸二酯酶V将含有它的药物组合物用作阳性的治疗剂。构成：由式（1）表示的新型吡唑嘧啶衍生物，其中R 1和R 2独立地为C 1 -C 6烷基或C 3 -C 6环烷基; R3是取代或未取代的C1-C6烷基，C3-C6环烷基或C3-C6烯基; 且X为O或NR 4，其中R 4为氢，OH或C 1 -C 6烷基，C 3 -C 6环烷基或被烷氧基取代或未取代的C 3 -C 6烯基。 其通过以下步骤制备：通过硫酮反应将式（2）的吡唑并嘧啶酮转化为式（3）的吡唑并嘧啶硫酮; 将式（3）的化合物氯化为式（4）的氯砜化合物，并使式（4）的化合物与仲胺反应以制备式（1）的最终化合物。

公开(公告)号：KR1020020078202A

公开(公告)日：2002-10-18

申请号：KR1020010018228

申请日：2001-04-06

Applicant: 한국과학기술연구원

Inventor： 진창배 ,  김동현 ,  이용섭 ,  정경자 ,  김형자

IPC: A61K31/70

Abstract: PURPOSE: A composition for the prevention and treatment of ischemic disease containing aloesin as an effective ingredient and a preparation containing the same is provided. Because aloesin as an aloe component has an excellent neuroprotective effect and nerve-ethological recovering effect, the composition containing the same can be effectively used in treatment of nerve cell and tissue damage caused by cerebral ischemia. CONSTITUTION: The composition for prevention and treatment of ischemia disease contains aloesin of the formula 1 £8-C-β -D-glucopyranosyl-7-hydroxy-5-methyl-2-(2-oxopropyl)-4H-1-benzopyran-4-one|, a pharmaceutically acceptable salt, hydrate or solvate or isomer and a pharmaceutically acceptable carrier thereof. The composition is formulated into a tablet, hard and soft gelatin capsule, liquid, suspension, injection, ointment, cream, gel or lotion. The composition is a neuroprotective composition for the prevention and treatment of ischemic apoplexy or concussion and a heart protecting composition for the prevention and treatment of ischemic myocardial infarction.

Abstract translation: 目的：提供一种预防和治疗含有芦荟素作为有效成分的缺血性疾病的组合物和含有它们的制剂。 因为作为芦荟成分的芦荟素具有优异的神经保护作用和神经病理恢复效果，所以含有该芦荟成分的组合物可有效地用于治疗由脑缺血引起的神经细胞和组织损伤。 构成：用于预防和治疗缺血性疾病的组合物含有式1的8-C-β-D-吡喃葡萄糖基-7-羟基-5-甲基-2-（2-氧代丙基）-4H-1-苯并吡喃-2-酮的芦荟碱， 4-酮|，其药学上可接受的盐，水合物或溶剂合物或其异构体及其药学上可接受的载体。 将组合物配制成片剂，硬和软明胶胶囊，液体，悬浮液，注射剂，软膏，霜剂，凝胶或洗剂。 该组合物是用于预防和治疗缺血性中风或脑震荡的神经保护组合物和用于预防和治疗缺血性心肌梗死的心脏保护组合物。

公开(公告)号：KR1020020017675A

公开(公告)日：2002-03-07

申请号：KR1020000051165

申请日：2000-08-31

Applicant: 김복량 ,  박래길 ,  한국과학기술연구원

Inventor： 김복량 ,  정헌택 ,  김동현 ,  박래길 ,  문성록 ,  오현숙

IPC: A61K36/539 ,  A61P35/00

Abstract: PURPOSE: The titled inhibitor containing a Scutellaria baicalensis George extract as a main component is provided which has an effect on suppressing carcinogenesis and can be used for prevention of cancer generated in an organ in the body such as liver cancer, stomach cancer, esophageal cancer, lung cancer, breast cancer or the like. CONSTITUTION: This carcinogenesis inhibitor is obtained by extracting a Scutellaria baicalensis George and can suppress carcinogenesis by expression of glutathiones S-transferase(GST) Yc1/2 to transfer carcinogenic substances to nontoxicity before DNA of a cell is damaged. The agent can formulate to be administered orally or parenterally at a dose of 11 to 500mg/kg/day.

Abstract translation: 目的：提供含有黄芩提取物作为主要成分的标题抑制剂，其具有抑制致癌作用的作用，并且可用于预防身体器官中产生的癌症，例如肝癌，胃癌，食管癌， 肺癌，乳腺癌等。 构成：这种致癌抑制剂是通过提取黄芩获得的，并且可以通过表达谷胱甘肽S-转移酶（GST）Yc1 / 2来抑制致癌作用，以在细胞DNA损伤之前将致癌物质转移到无毒性。 该制剂可以配制成口服或肠胃外给药，剂量为11至500mg / kg /天。

公开(公告)号：KR101750745B1

公开(公告)日：2017-06-27

申请号：KR1020160007916

申请日：2016-01-22

Applicant: 한국과학기술연구원

Inventor： 정경윤 ,  김동현 ,  디키수산토 ,  윤여조 ,  조병원 ,  오시형 ,  장원영

IPC: G01N1/44 ,  G01N23/20 ,  G01N23/223 ,  G01N23/207

CPC classification number: G01N23/20008 ,  G01N23/207

Abstract: 투과형엑스선회절분석장치용퍼니스및 이를이용한투과형엑스선회절분석장치가개시된다. 본발명의일 실시예에따른투과형엑스선회절분석장치용퍼니스는시료가수용된쿼츠캐필러리(quartz capillary)에인접하게배치되어시료를가열하는시료가열부; 및쿼츠캐필러리와시료가열부를감싸도록배치되며, 가열된시료가열적평형상태를유지하도록단열기능을가지는본체부를포함한다.

Abstract translation: 透射型X射线衍射装置的炉和使用该炉的透射型X射线衍射装置被公开。 根据本发明的一个方面，提供了一种用于透射X射线衍射装置的炉子，包括：容纳样品的石英毛细管; 石英毛细管和样品加热单元，并且包括具有绝热功能的主体部分，使得加热的样品保持热平衡状态。

公开(公告)号：KR1020030088906A

公开(公告)日：2003-11-21

申请号：KR1020020026650

申请日：2002-05-15

Applicant: 한국과학기술연구원

Inventor： 이용섭 ,  김동현 ,  김형자 ,  박호군

IPC: A61K31/353

Abstract: PURPOSE: Provided is a composition for treating sexual dysfunction which contains a flavonoid compound represented by the formula 1 or 2, and an extract of Sophora flavescens containing them, as active ingredients. The composition inhibits on cGMP-PDE5 and is thus useful for the prevention and treatment of sexual disfunction. CONSTITUTION: A composition for treating sexual dysfunction is characterized by containing, as active ingredients, a flavonoid compound represented by the formula 1 or 2, wherein R1 is a unsubstituted or hydroxy group-substituted linear or branched alkenyl group; R2 is hydrogen, hydroxy or C1-C3 alkoxy; R3 and R4 are individually hydrogen or a hydroxy group; and a dotted line represents single or double bond, and its pharmaceutically acceptable salt, hydrates, solvate, isomer or their mixture.

Abstract translation: 目的：提供一种用于治疗性功能障碍的组合物，其含有由式1或2表示的类黄酮化合物和含有它们的苦参皂甙提取物作为活性成分。 该组合物抑制cGMP-PDE5，因此可用于预防和治疗性功能障碍。 构成：用于治疗性功能障碍的组合物的特征在于，含有作为活性成分的由式1或2表示的类黄酮化合物，其中R1是未取代的或羟基取代的直链或支链烯基; R2是氢，羟基或C1-C3烷氧基; R3和R4分别是氢或羟基; 虚线表示单键或双键，以及其药学上可接受的盐，水合物，溶剂合物，异构体或它们的混合物。